A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: A randomized, double-blind study

This publication has 11 references indexed in Scilit:

• The efficacy of GR38032F, an Antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1988
• Oral Metoclopramide With or Without Diphenhydramine: Potential for Prevention of Late Nausea and Vomiting Induced by Cisplatin
  JNCI Journal of the National Cancer Institute, 1988
• Toxicity, Physical Function and Everyday Activity Reported by Patients with Inoperable Non-Small Cell Lung Cancer in a Randomized Trial (Chemotherapy Versus Radiotherapy)
  Acta Oncologica, 1988
• PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST
  The Lancet, 1987
• Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.
  Journal of Clinical Oncology, 1987
• The Management of Chemotherapy-Induced Nausea and Vomiting
  Medical Clinics of North America, 1987
• Metoclopramide
  Drugs, 1983
• Incidence of nausea and vomiting with cytotoxic chemotherapy: a prospective randomised trial of antiemetics.
  BMJ, 1979
• A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer.A southeastern cancer study group project
  Cancer, 1977